CDC-RFA-DP-24-0053: Enhancing Reviews and Surveillance to Eliminate Maternal Mortality
Closed
This grant is closed. A newer notice from the same program is forecast: Statewide Perinatal Quality Collaboratives: Improving Perinatal Care and Outcomes (CDC-RFA-DP-27-0043). Status: Expected deadline May 3, 2027. It is in our archive of Centers for Disease Control - NCCDPHP notices from 2024.
Centers for Disease Control - NCCDPHP offered grants to any type of organization. It expected to make about 59 awards worth $134 million in total. Applications closed on May 23, 2024.
From the official notice on Grants.gov, last changed April 30, 2024. Checked November 7, 2026.
- Total funding$134 million
- Expected awards59
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 18, 2024 |
|---|---|
| Deadline | May 23, 2024 |
| Archived by Grants.gov | June 22, 2024 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
CDC will consider any applications non-responsive, and it will not receive further review, if the following documents are not submitted as specified in the collaboration section of this NOFO. CDC will fund the recognized authority to implement a MMRC in each State, US territory or Freely Associated State, or the District of Columbia. The recognized entity must provide the following documents in order to provide evidence of eligibility. Additional information is further described under Collaborations.
Is this a realistic fit?
- Most of the program's money (65% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
Purpose The Centers for Disease Control and Prevention (CDC) announces the availability of funds to support agencies and organizations that coordinate and manage Maternal Mortality Review Committees to identify and characterize pregnancy-related deaths for preventability, abstract clinical/non-clinical data into a standard data system, conduct informant interviews to inform individual case review, and enter information into a standard data system within 2 years of death. This NOFO aims to improve the overall timeliness and availability of information on strategies for prevention of pregnancy-related deaths and reduction of disparities in pregnancy-related mortality nationally.
Who has won Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs grants before
From fiscal 2021 to 2025, Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs (93.946) awarded $181 million across 261 grant awards, an average of $692,085 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 1 | $12.6 million |
| Massachusetts Department of Public Health | Massachusetts | 5 | $4.2 million |
| Michigan Department of Health and Human Services | Michigan | 4 | $4.2 million |
| Health Services Kentucky Cabinet for | Kentucky | 6 | $4.1 million |
| National Institute for Childrens Health Quality Inc | Massachusetts | 2 | $4.0 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-DP-27-0043, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DP-24-0053 still open?
No. It closed on May 23, 2024. A newer notice is forecast: CDC-RFA-DP-27-0043, expected deadline May 3, 2027.
Who can apply for Enhancing Reviews and Surveillance to Eliminate Maternal Mortality?
Centers for Disease Control - NCCDPHP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Enhancing Reviews and Surveillance to Eliminate Maternal Mortality?
Closed May 23, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $134 million in total across about 59 awards.
Who has won Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs grants before?
The largest recipients over five fiscal years were National Foundation for the Centers for Disease Control & Prevention, Inc., Massachusetts Department of Public Health, Michigan Department of Health and Human Services. The program made 261 awards worth $181 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)